nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.12.2010 | NON-THEMATIC REVIEW

Regulatory T cells and breast cancer: implications for immunopathogenesis

verfasst von: Maria Angelica Ehara Watanabe, Julie Massayo Maeda Oda, Marla Karine Amarante, Julio Cesar Voltarelli

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Current understanding of the role of several cancer risk factors is more comprehensive, as reported for a number of sites, including the brain, colon, breasts, and ovaries. Despite such advances, the incidence of breast cancer continues to increase worldwide. Signals from the microenviroment have a profound influence on the maintenance or progression cancers. Although T cells present the most important immunological response in tumor growth in the early stages of cancer, they become suppressive CD4⁺ and CD8⁺ regulatory T cells (Tregs) after chronic stimulation and interactions with tumor cells, thus promoting rather than inhibiting cancer development and progression. Tregs have an important marker protein which is FoxP3, though it does not necessarily confer a Treg phenotype when expressed in CD4⁺ T lymphocytes. High Treg levels have been reported in peripheral blood, lymph nodes, and tumor specimens from patients with different types of cancer. The precise mechanisms by which Tregs suppress immune cell functions remain unclear, and there are reports of both direct inhibition through cell–cell contact and indirect inhibition through the secretion of anti-inflammatory mediators such as interleukin. In this review, we present the molecular and immunological aspects of Treg cells in the metastasis of breast cancer.

Chu, D., & Lu, J. (2008). Novel therapies in breast cancer: What is new from ASCO 2008. Journal of Hematology Oncology, 1, 1–16.CrossRef

Kásler, M., Polgár, C., & Fodor, J. (2009). Current status of treatment for early-stage invasive breast cancer. Orvosi Hetilap, 150, 1013–1021.CrossRefPubMed

Benz, C. C. (2008). Impact of aging on the biology of breast cancer. Impact of aging on the biology of breast cancer. Critical Reviews in Oncology/Hematology, 66(1), 65–74.CrossRefPubMed

Lacroix, M., Toillon, R. A., & Leclercq, G. (2004). Stable ‘portrait’ of breast tumors during progression: Data from biology, pathology and genetics. Endocrine-Related Cancer, 11, 497–522.CrossRefPubMed

Rakha, E. A., El-Sayed, M. E., Reis-Filho, J., & Ellis, I. O. (2009). Patho-biological aspects of basal-like breast cancer. Breast Cancer Research and Treatment, 113, 411–422.CrossRefPubMed

Beckmann, M. W., Niederacher, D., Schnürch, H. G., Gusterson, B. A., & Bender, H. G. (1997). Multistep carcinogenesis of breast cancer and tumour heterogeneity. Journal of Molecular Medicine, 75, 429–439.CrossRefPubMed

Perou, C. M., Sorlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., et al. (2000). Molecular portraits of human breast tumours. Nature, 406, 747–752.CrossRefPubMed

Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of USA, 98, 10869–10874.CrossRef

Sorlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., et al. (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of USA, 100, 8418–8423.CrossRef

10.

Bertucci, F., Houlgatte, R., Benziane, A., Granjeaud, S., Adélaïde, J., Tagett, R., et al. (2000). Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Human Molecular Genetics, 9, 2981–2991.CrossRefPubMed

11.

Bergamaschi, A., Kim, Y. H., Wang, P., Sorlie, T., Hernandez-Boussard, T., & Lonning, P. E. (2006). Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes, Chromosomes & Cancer, 45, 1033–1040.CrossRef

12.

Chin, K., DeVries, S., Fridlyand, J., Spellman, P. T., Roydasgupta, R., & Kuo, W. L. (2006). Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell, 10, 529–541.CrossRefPubMed

13.

Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., et al. (2006). A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell, 10, 515–527.CrossRefPubMed

14.

Aoki, M. N., da Silva do Amaral Herrera, A. C., Amarante, M. K., do Val Carneiro, J. L., Fungaro, M. H., & Watanabe, M. A. (2009). CCR5 and p53 codon 72 gene polymorphisms: Implications in breast cancer development. International Journal of Molecular Medicine, 23, 429–435.PubMed

15.

Hori, S., Nomura, T., & Sakaguchi, S. (2003). Control of regulatory T cell development by the transcription factor FoxP3. Science, 299, 1057–1061.CrossRefPubMed

16.

Bernardes, S. S., Borges, I. K., Lima, J. E., de Azevedo Oliveira Milanez, P., Costa, I. C., Felipe, I., et al. (2010). Involvement of regulatory T cells in HIV immunopathogenesis. Current HIV Research, 8, 340–346.CrossRefPubMed

17.

Rosenberg, S. A. (2001). Progress in human tumour immunology and immunotherapy. Nature, 411, 380–384.CrossRefPubMed

18.

Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004). The immunobiology of cancer immunosurveillance and immunoediting. Immunity, 21, 137–148.CrossRefPubMed

19.

Dougan, M., & Dranoff, G. (2009). The immune response to tumors. Current Protocols in Immunology. Chapter 20, Unit 20.11.

20.

Amarante, M. K., & Watanabe, M. A. E. (2009). The possible involvement of virus in breast cancer. Journal of Cancer Research and Clinical Oncology, 135(3), 329–337.CrossRefPubMed

21.

Standish, L. J., Sweet, E. S., Novack, J., Wenner, C. A., Bridge, C., Nelson, A., et al. (2008). Breast cancer and the immune system. Journal of the Society for Integrative Oncology, 6, 158–168.PubMed

22.

Kazbariene, B. (2009). Tumor and immunity. Medicina, 45, 162–167.PubMed

23.

Tan, T. T., & Coussens, L. M. (2007). Humoral immunity, inflammation and cancer. Current Opinion in Immunology, 19, 209–216.CrossRefPubMed

24.

DeNardo, D. G., & Coussens, L. M. (2007). Inflammation and breast cancer. Balancing immune response: Crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Research, 9, 212.CrossRefPubMed

25.

Wang, R. F. (2008). CD8⁺ regulatory T cells, their suppressive mechanisms, and regulation in cancer. Human Immunology, 69, 811–814.CrossRefPubMed

26.

Sakaguchi, S., Wing, K., & Miyara, M. (2007). Regulatory T cells—A brief history and perspective. European Journal of Immunology, 37(Suppl 1), S116–S123.CrossRefPubMed

27.

Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995). Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. Journal of Immunology, 155(3), 1151–1164.

28.

Shevach, E. M. (2002). CD4⁻CD25⁻ suppressor T cells: More questions than answers. Nature Reviews. Immunology, 2, 389–400.PubMed

29.

Wood, K. J., & Sakaguchi, S. (2003). Regulatory lymphocytes: Regulatory T cells in transplantation tolerance. Nature Review Immunology, 3, 199–210.CrossRef

30.

Maloy, K. J., & Powrie, F. (2001). Regulatory T cells in the control of immune pathology. Nature Immunology, 2, 816–822.CrossRefPubMed

31.

Li, M. O., & Flavell, R. A. (2008). TGF-beta: A master of all T cell trades. Cell, 134, 392–404.CrossRefPubMed

32.

Feuerer, M., Hill, J. A., Mathis, M., & Benoist, C. (2009). FoxP3⁺ regulatory T cells: Differentiation, specification, subphenotypes. Nature Immunolgy, 10, 689–695.CrossRef

33.

Curti, A., Pandolfi, S., Valzasina, B., Aluigi, M., Isidori, A., Ferri, E., et al. (2007). Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25S into CD25R T regulatory cells. Blood, 109, 2871–2877.PubMed

34.

Thornton, A. M., & Shevach, E. M. (1998). CD4⁺CD25⁺ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. The Journal of Experimental Medicine, 188, 287–296.CrossRefPubMed

35.

Wang, H. Y., Peng, G., Guo, Z., Shevach, E. M., & Wang, R. F. (2005). Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4⁺ regulatory T cells. Journal of Immunology, 174, 2661–2670.

36.

Roncarolo, M. G., Gregori, S., Battaglia, M., Bacchetta, R., Fleischhauer, K., & Levings, M. K. (2006). Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunological Reviews, 212, 28–50.CrossRefPubMed

37.

Weiner, H. L. (2001). Induction and mechanism of action of transforming growth factor beta-secreting Th3 regulatory cells. Immunological Reviews, 182, 207–214.CrossRefPubMed

38.

Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003). FoxP3 programs the development and function of CD4⁺CD25 regulatory T cells. Nature Immunology, 4, 330–336.CrossRefPubMed

39.

Bacchetta, R., Passerini, L., Gambineri, E., Daí, M., Allan, S. E., Perroni, L., et al. (2006). Defective regulatory and effector T cell functions in patients with FoxP3 mutations. The Journal of Clinical Investigation, 116, 1713–1722.CrossRefPubMed

40.

Gavin, M. A., Torgerson, T. R., Houston, E., DeRoos, P., Ho, W. Y., Stray-Pedersen, A., et al. (2006). Single-cell analysis of normal and FOXP3-mutant human T cells: FoxP3 expression without regulatory T cell development. Proceedings of the National Academy of Sciences of the USA, 103, 6659–6664.CrossRefPubMed

41.

Roncador, G., Brown, P. J., Maestre, L., Hue, S., Martínez-Torrecuadrada, J. L., Ling, K. L., et al. (2005). Analysis of FoxP3 protein expression in human CD4(+)CD25(+) regulatory T cells at the single-cell level. European Journal of Immunology, 35, 1681–1691.CrossRefPubMed

42.

Li, B., Saouaf, S. J., Samanta, A., Shen, Y., Hancock, W. W., & Greene, M. I. (2007). Biochemistry and therapeutic implications of mechanisms involved in FoxP3 activity in immune suppression. Current Opinion in Immunology, 19, 583–588.CrossRefPubMed

43.

Wu, Y., Borde, M., Heissmeyer, V., Feuerer, M., Lapan, A. D., Stroud, J. C., et al. (2006). FoxP3 controls regulatory T cell function through cooperation with NFAT. Cell, 126, 375–387.CrossRefPubMed

44.

Cruvinel, W. M., Mesquita, D., Jr., Araújo, J. A. P., Salmazi, K. C., Kállas, E. G., Andrade, L. E. C., et al. (2008). Natural regulatory T cells in rheumatic diseases. Revista Brasileira de Reumatologia, 48, 342–355.CrossRef

45.

Lin, H., Sun, X. F., Zhen, Z. J., Xia, Y., Ling, J. Y., Huang, H. Q., et al. (2009). Correlation between peripheral blood CD4⁺CD25^highCD127^low regulatory T cell and clinical characteristics of patients with non-Hodgkin’s lymphoma. Ai Zheng, 28(11), 1186–1192.PubMed

46.

Whiteside, T. L. (2006). Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Seminars in Cancer Biology, 16(1), 3–15.CrossRefPubMed

47.

Mansfield, A. S., Heikkila, P. S., Vaara, A. T., von Smitten, K. A., Vakkila, J. M., & Leidenius, M. H. (2009). Simultaneous FoxP3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer, 9, 231.CrossRefPubMed

48.

Zhou, L., Lopes, J. E., Chong, M. M. W., Ivanov, I. I., Min, R., Victora, G. D., et al. (2008). TGF-β-induced FoxP3 inhibits TH17 cell differentiation by antagonizing RORγt function. Nature, 453, 236–240.CrossRefPubMed

49.

Voo, K. S., Wang, Y. H., Santori, F. R., Boggiano, C., Wang, Y. H., Arima, K., et al. (2009). Identification of IL-17-producing FoxP3⁺ regulatory T cells in humans. Proceedings of the National Academy of Sciences of USA, 106, 4793–4798.CrossRef

50.

Beyer, M., Kochanek, M., Giese, T., Endl, E., Weihrauch, M. R., Knolle, P. A., et al. (2006). In vivo peripheral expansion of naive CD4⁺CD25^highFoxP3⁺ regulatory T cells in patients with multiple myeloma. Blood, 107, 3940–3949.CrossRefPubMed

51.

Wang, H. Y., & Wang, R. F. (2007). Regulatory T cells and cancer. Current Opinion in Immunology, 19, 217–223.CrossRefPubMed

52.

Liu, Z., Kim, J. H., Falo, L. D., Jr., & You, Z. (2009). Tumor regulatory T cells potently abrogate antitumor immunity. Journal of Immunology, 182, 6160–6167.CrossRef

53.

Konwar, R., Chaudhary, P., Kumar, S., Mishra, D., Chattopadhyay, N., & Bid, H. K. (2009). Breast cancer risks associated with polymorphisms of IL-1RN and IL-4 gene in Indian women. Oncology Research, 17, 367–372.CrossRefPubMed

54.

Zhou, X., Bailey-Bucktrout, S., Jeker, L. T., & Bluestone, J. A. (2009). Plasticity of CD4(+) FoxP3(+) T cells. Current Opinion in Immunology, 21, 281–285.CrossRefPubMed

55.

Kosmaczewska, A., Ciszak, L., Potoczek, S., & Frydecka, I. (2008). The significance of Treg cells in defective tumor immunity. Archivum Immunologiae et Therapie Experimentalis, 56, 181–191.CrossRef

56.

Gupta, S., Joshi, K., Wig, J. D., & Arora, S. K. (2007). Intratumoral FoxP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis. Acta Oncológica, 46, 792–797.CrossRefPubMed

57.

Karanikas, V., Speletas, M., Zamanakou, M., Kalala, F., Loules, G., Kerenidi, T., et al. (2008). FoxP3 expression in human cancer cells. Journal of Translational Medicine, 6, 19.CrossRefPubMed

58.

Liu, L., Wu, G., Yao, J. X., Liu, L., Wu, G., Yao, J. X., et al. (2008). CD4⁺CD25^high regulatory cells in peripheral blood of cancer patients. Neuro Endocrinology Letters, 29, 240–245.PubMed

59.

Bates, G. J., Fox, S. B., Han, C., Leek, R. D., Garcia, J. F., Harris, A. L., et al. (2006). Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. Journal of Clinical Oncology, 24, 5373–5380.CrossRefPubMed

60.

Liu, Y., & Zheng, P. (2007). FoxP3 and breast cancer: Implications for therapy and diagnosis. Pharmacogenomics, 8, 1485–1487.CrossRefPubMed

61.

Zuo, T., Wang, L., Morrison, C., Chang, X., Zhang, H., Li, W., et al. (2007). FoxP3 is an X-linked breast cancer suppressor gene and an important repressor of HER-2/ErbB2 oncogene. Cell, 129, 1275–1286.CrossRefPubMed

62.

Ohara, M., Yamaguchi, Y., Matsuura, K., Murakami, S., Arihiro, K., & Okada, M. (2009). Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer. Cancer Immunology Immunotherapy: CII, 58, 441–447.CrossRef

63.

Ladoire, S., Arnould, L., Mignot, G., Coudert, B., Rébé, C., Chalmin, F., et al. (2010). Presence of FoxP3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Research and Treatment, doi:10.1007/s10549-010-0831-1

64.

Selenko-Gebauer, N., Majdic, O., Szekeres, A., Höfler, G., Guthann, E., Korthäuer, U., et al. (2003). B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. Journal of Immunology, 170, 3637–3644.

65.

Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002). Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proceedings of the National Academy of Sciences of the USA, 99, 12293–12297.CrossRefPubMed

66.

Ghebeh, H., Barhoush, E., Tulbah, A., Elkum, N., Al-Tweigeri, T., & Dermime, S. (2008). FoxP3⁺ Tregs and B7-H1⁺/PD-1⁺ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer, 23, 8–57.

67.

Berger, C. L., Tigelaar, R., Cohen, J., Mariwalla, K., Trinh, J., Wang, N., et al. (2005). Cutaneous T cell lymphoma: Malignant proliferation of T regulatory cells. Blood, 105, 1640–1647.CrossRefPubMed

68.

Karube, K., Ohshima, K., Tsuchiya, T., Yamaguchi, T., Kawano, R., Suzumiya, J., et al. (2004). Expression of FoxP3, a key molecule in CD4⁺CD25⁺ regulatory T cells, in adult T cell leukaemia/lymphoma cells. British Journal Haematology, 126, 81–84.CrossRef

69.

Liyanage, U. K., Moore, T. T., Joo, H. G., Tanaka, Y., Herrmann, V., Doherty, G., et al. (2002). Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. Journal of Immunology, 169, 2756–2761.

70.

Perez, S. A., Karamouzis, M. V., Skarlos, D. V., Ardavanis, A., Sotiriadou, N. N., Iliopoulou, E. G., et al. (2007). CD4⁺CD25⁺ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clinical Cancer Research, 13, 2714–2721.CrossRefPubMed

71.

Wolf, A. M., Wolf, D., Steurer, M., Gastl, G., Gunsilius, E., Grubeck-Loebenstein, B., et al. (2003). Increase of regulatory T cells in the peripheral blood of cancer patients. Clinical Cancer Research, 9(2), 606–612.PubMed

72.

Bi, Y., Wei, L., Mao, H. T., Zhang, L., & Zuo, W. S. (2008). Expressions of Fas, CTLA-4 and RhoBTB2 genes in breast carcinoma and their relationship with clinicopathological factors. Zhonghua ZhongLiu Za Zhi, 30, 749–753.

73.

Jaberipour, M., Habibagahi, M., Hosseini, A., Habibabad, S. R., Talei, A., & Ghaderi, A. (2010). Increased CTLA-4 and FOXP3 transcripts in peripheral blood mononuclear cells of patients with breast cancer. Pathology Oncology Research, doi:10.1007/s12253-010-9256-8

74.

Raskin, L., Rennert, G., & Gruber, S. B. (2009). FoxP3 germline polymorphisms are not associated with risk of breast cancer. Cancer Genetics and Cytogenetics, 190, 40–42.CrossRefPubMed

75.

Fidler, I. J. (2003). The pathogenesis of cancer metastasis: The ‘seed and soil’ hypothesis revisited. Nature Reviews. Cancer, 3, 453–458.CrossRefPubMed

76.

Gupta, G. P., & Massagué, J. (2006). Cancer metastasis: Building a framework. Cell, 127, 679–695.CrossRefPubMed

77.

Audia, S., Nicolas, A., Cathelin, D., Larmonier, N., Ferrand, C., Foucher, P., et al. (2007). Increase of CD4⁺ CD25⁺+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: A phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4⁺CD25⁺ T lymphocytes. Clinical and Experimental Immunology, 150(3), 523–530.CrossRefPubMed

78.

Rech, A. J., Mick, R., Kaplan, D. E., Chang, K. M., Domchek, S. M., & Vonderheide, R. H. (2010). Homeostasis of peripheral FoxP3(+) CD4 (+) regulatory T cells in patients with early and late stage breast cancer. Cancer Immunology, Immunotherapy, 59(4), 599–607.CrossRefPubMed

79.

Aruga, T., Suzuki, E., Saji, S., Horiguchi, S., Horiguchi, K., Sekine, S., et al. (2009). A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer. Oncology Reports, 22, 273–278.PubMed

80.

Merlo, A., Casalini, P., Carcangiu, M. L., Malventano, C., Triulzi, T., Mènard, S., et al. (2009). FoxP3 expression and overall survival in breast cancer. Journal of Clinical Oncology, 27, 1746–1752.CrossRefPubMed

81.

Carneiro, J. L. V., Nixdorf, S. L., Mantovani, M. S., da Silva do Amaral Herrera, A. C., Aoki, M. N., Amarante, M. K., et al. (2009). Plasma malondialdehyde levels and CXCR4 expression in peripheral blood cells of breast cancer patients. Journal of Cancer Research and Clinical Oncology, 135, 997–1004.CrossRef

82.

Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., et al. (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature, 410(6824), 50–56.CrossRefPubMed

83.

Shimizu, Y., Dobashi, K., Imai, H., Sunaga, N., Ono, A., Sano, T., et al. (2009). CXCR4⁺FOXP3⁺CD25⁺ lymphocytes accumulate in CXCL12-expressing malignant pleural mesothelioma. International Journal of Immunopathology and Pharmacology, 22, 43–51.PubMed

84.

Ishida, T., & Ueda, R. (2006). CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Science, 97(11), 1139–1146.CrossRefPubMed

85.

Mougiakakos, D., Choudhury, A., Lladser, A., Kiessling, R., & Johansson, C. C. (2010). Regulatory T cells in cancer. Advances in Cancer Research, 107, 57–117.CrossRefPubMed

86.

Xu, L., Xu, W., Qiu, S., & Xiong, S. (2010). Enrichment of CCR6(+)Foxp3(+) regulatory T cells in the tumor mass correlates with impaired CD8(+) T cell function and poor prognosis of breast cancer. Clinical Immunology, 135, 466–475.CrossRefPubMed

87.

Tannock, I. F., Hill, R. P., Bristow, R. G., & Harrington, L. (2005). The basic science of oncology. New York: McGraw-Hill.

88.

Nguyen, D. X., & Massagué, J. (2007). Genetic determinants of cancer metastasis. Nature Reviews Genetics, 8, 341–352.CrossRefPubMed

89.

Alam, S. M., Clark, J. S., George, W. D., & Campbell, A. M. (1993). Altered lymphocyte populations in tumour invaded nodes of breast cancer patients. Immunology Letters, 35(3), 229–234.CrossRefPubMed

90.

Nakamura, R., Sakakibara, M., Nagashima, T., Sangai, T., Arai, M., Fujimori, T., et al. (2009). Accumulation of regulatory T cells in sentinel lymph nodes is a prognostic predictor in patients with node-negative breast cancer. European Journal of Cancer, 45, 2123–2131.CrossRefPubMed

91.

Matsuura, K., Yamaguchi, Y., Osaki, A., Ohara, M., Okita, R., Emi, A., et al. (2009). FoxP3 expression of micrometastasis-positive sentinel nodes in breast cancer patients. Oncology Reports, 22(5), 1181–1187.CrossRefPubMed

92.

Akhurst, R. J., & Derynck, R. (2001). TGF-beta signalling in cancer—A double-edged sword. Trends in Cell Biology, 11, S44–S51.PubMed

93.

Kalluri, R., & Zeisberg, M. (2006). Fibroblasts in cancer. Nature Reviews Cancer, 6, 392–401.CrossRefPubMed

94.

Pollard, J. W. (2004). Tumour-educated macrophages promote tumor progression and metastasis. Nature Reviews. Cancer, 4, 71–78.CrossRefPubMed

95.

Wels, J., Kaplan, R. N., Rafii, S., & Lyden, D. (2008). Migratory neighbors and distant invaders: Tumor-associated niche cells. Genes & Development, 22, 559–574.CrossRef

96.

Gobert, M., Treilleux, I., Bendriss-Vermare, N., Bachelot, T., Goddard-Leon, S., Arfi, V., et al. (2009). Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Research, 69(5), 2000–2009.CrossRefPubMed

97.

Zheng, Y., & Rudensky, A. Y. (2007). Foxp3 in control of the regulatory T cell lineage. Nature Immunology, 8, 457–462.CrossRefPubMed

98.

Kodama, J., Hasengaowa, Kusumoto, T., Seki, N., Matsuo, T., Ojima, Y., et al. (2007). Association of CXCR4 and CCR7 chemokine receptorexpression and lymph node metastasis in human cervical cancer. Annals of Oncology, 18, 70–76.CrossRefPubMed

99.

Pitkin, L., Luangdilok, S., Corbishley, C., Wilson, P. O., Dalton, P., Bray, D., et al. (2007). Expression of CC chemokine receptor 7 in tonsillar cancer predicts cervical nodal metastasis, systemic relapse and survival. British Journal of Cancer, 97, 670–677.CrossRefPubMed

100.

Lu, H. (2009). FoxP3 expression and prognosis: Role of both the tumor and T cells. Journal of Clinical Oncology, 27(11), 1735–1736.CrossRefPubMed

Titel: Regulatory T cells and breast cancer: implications for immunopathogenesis
verfasst von: Maria Angelica Ehara Watanabe
Julie Massayo Maeda Oda
Marla Karine Amarante
Julio Cesar Voltarelli
Publikationsdatum: 01.12.2010
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 4/2010
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-010-9247-y

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Regulatory T cells and breast cancer: implications for immunopathogenesis

Abstract

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2010

Erratum to: microRNAs and lung cancer: tumors and 22-mers

Malignant melanoma as a target malignancy for the study of the anti-metastatic properties of the heparins

Distant metastases do not metastasize

Perspectives on the mesenchymal origin of metastatic cancer

DNA methylation or histone modification status in metastasis and angiogenesis-related genes: a new hypothesis on usage of DNMT inhibitors and S-adenosylmethionine for genome stability

Induction chemotherapy response and recurrence rates in correlation with N0 or N+ stage in oral squamous cell cancer (OSCC)

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie